Pioneering

the development and
manufacture of off-the-shelf,
universally implantable,

bioengineered
human tissues

Pioneering

the development and
manufacture of off-the-shelf,
universally implantable,

bioengineered
human tissues

Luna_Image

The Humacyte Human Acellular VesselTM (HAV)

is a regenerative vascular conduit
currently in various stages of clinical trials
targeting multiple vascular applications, including
vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. By adapting our platform, we may create small diameter HAVs to potentially treat conditions such as coronary artery disease and Type I diabetes, and someday, organs for transplant.

The HAV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Innovation at
commercial scale

Humacyte Global, Inc. (Nasdaq: HUMA) has developed the LUNA200™ bioengineering system which produces investigational Human Acellular Vessels designed to improve the lives of patients and transform the practice of medicine. Located in Durham, N.C.,
the company was founded in 2004 by Laura Niklason, MD, Ph.D., a world leader in tissue engineering and the Chief Executive Officer of Humacyte, along with Drs. Juliana Blum and Shannon Dahl.

Scroll to Top